Tirzepatide Cost in 2026: Brand vs. Compounded Pricing

Tirzepatide cost ranges from about $25 to over $1,200 per month depending on which product you buy, who's dispensing it, and what your insurance does. That 48-fold spread is wide enough to change whether the drug is realistic for you, so the details matter. Tirzepatide cost is not a single number, it's a decision tree, and the branches have shifted meaningfully since the FDA resolved the tirzepatide shortage in December 2024.

This guide covers US adult pricing, insurance pathways, and the post-March-2025 compounded market. It does not cover pediatric dosing, international pricing outside the US, clinical efficacy comparisons against other GLP-1 drugs, or prescribing criteria beyond cost-relevant context. For clinical decisions, work with a licensed prescriber.

How much does tirzepatide cost in 2026?

Here's what tirzepatide costs across the main 2026 paths, side by side, before getting into the details of each.

Prices reflect published pricing as of April 19, 2026. Compounded figures are wide because pricing varies by provider and shifted significantly after the March 2025 FDA deadline, confirm directly with any provider before enrolling.

How much does Zepbound or Mounjaro cost without insurance?

Tirzepatide is the same active ingredient in two different Eli Lilly and Company products, approved for two different conditions:

• Zepbound, FDA approved for chronic weight management and, since early 2025, for moderate-to-severe obstructive sleep apnea in adults with obesity.
• Mounjaro, FDA approved for Type 2 diabetes mellitus.

The drug molecule, manufacturing site, and clinical effect are identical at equivalent doses. The pricing is nearly identical too. According to GoodRx's pharmacy-database pricing as of April 2026, the list price for Zepbound is approximately $1,086 for a 28-day supply, and the list price for Mounjaro is approximately $1,080 per fill. Without insurance, retail pharmacies typically charge $1,000 to $1,200 or more per month, depending on dispensing margins.²³

At the list price, a patient paying out of pocket for Mounjaro would spend roughly $12,900 per year. For a patient maintained on tirzepatide indefinitely, which the SURMOUNT and SURPASS trial data suggest is often clinically appropriate for sustained weight-loss or glycemic response, that annual cost becomes a significant life decision rather than a short-term expense.⁵

How much is tirzepatide through LillyDirect?

In late 2024, Eli Lilly launched LillyDirect, a direct-to-consumer channel that sells single-dose vials of Zepbound at prices well below retail. Unlike the prefilled autoinjector pens sold at pharmacies, these vials require drawing the dose with a syringe, a small extra step, but the pricing savings are substantial.

LillyDirect Self-Pay Vial Prices (April 2026)

Source: Eli Lilly LillyDirect Self Pay Journey Program pricing, reported April 2026.⁴ Requires valid US prescription. Not combinable with the Zepbound savings card.

The Self Pay Journey Program is the single biggest change in tirzepatide cost economics since late 2024. A patient maintained at the maximum 15 mg dose who refills consistently pays $5,388 per year through LillyDirect, compared to roughly $13,000 at retail, a savings of nearly $8,000 annually for the same FDA-approved product from the same manufacturer.

A few practical notes on LillyDirect:

• This is brand-name Zepbound, made and shipped by Eli Lilly. It is not compounded, not generic, and not repackaged.
• Vials require a syringe draw. Eli Lilly provides the syringes; patients new to injections may want a pharmacist or clinician to walk through the first dose.
• LillyDirect is Zepbound-only. There is no equivalent self-pay vial program for Mounjaro, because Type 2 diabetes patients more frequently have insurance coverage that makes cash-pay unattractive.
• Eligibility has broadened over 2025 and 2026. The program now covers the 12.5 mg and 15 mg maintenance doses that were not initially available at launch.

How much is tirzepatide with insurance and a savings card?

Eli Lilly runs manufacturer savings programs for both branded products. The rules differ in detail but the structure is similar: commercial insurance required, federal program beneficiaries excluded.

Mounjaro Savings Card

Commercially insured patients can pay as little as $25 for a 1-, 2-, or 3-month supply of Mounjaro with the savings card. Maximum savings are structured by fill size:

• 1-month supply: up to $150 per prescription
• 2-month supply: up to $300 per prescription
• 3-month supply: up to $450 per prescription

The Mounjaro Savings Card has a separate $1,950 annual maximum in total savings per calendar year. For patients whose commercial insurance does not cover Mounjaro, a smaller discount, up to $463 off a 1-month prescription, may still apply.³

Zepbound Savings Card

Zepbound's program follows a similar pattern with a $25 monthly price for patients whose commercial insurance covers the drug, and a larger flat discount (up to approximately $550 off per fill) for patients whose commercial insurance does not cover Zepbound. Eligibility documents must be renewed periodically.

Who Savings Cards Exclude

Both cards are ineligible for patients enrolled in any federal healthcare program, including Medicare, Medicaid, TRICARE, and VA. This is the standard rule for manufacturer copay cards under US healthcare law and is not specific to tirzepatide.

How much does compounded tirzepatide cost?

Compounded tirzepatide from licensed 503A and 503B compounding pharmacies typically runs $150 to $600 per month in 2026, plus $40 to $100 in membership or consultation fees at many telehealth platforms.⁹ That pricing makes it the most affordable path for cash-pay patients, but the regulatory story behind it, and what "compounded" actually means in 2026, is worth understanding before enrolling.

From 2022 through most of 2024, tirzepatide sat on the FDA drug shortage list. During a shortage, federal law allows state-licensed compounding pharmacies (under section 503A of the Federal Food, Drug, and Cosmetic Act) and outsourcing facilities (under section 503B) to produce copies of FDA-approved products that would otherwise be prohibited. That shortage-era allowance made compounded tirzepatide a common cash-pay path through 2024.

The rules changed in 2025, and the compounded market adapted.

What Actually Happened

On December 19, 2024, the FDA determined the tirzepatide injection shortage was resolved, citing confirmed production and inventory capacity from Eli Lilly.¹ The Outsourcing Facilities Association sued to preserve compounding access. On March 5, 2025, a US district court in the Northern District of Texas (Outsourcing Facilities Association v. FDA, 4:24-cv-00953) denied the plaintiffs' preliminary injunction motion.¹

The FDA's compounding enforcement timeline followed immediately:

• State-licensed 503A pharmacies: The period of enforcement discretion for compounding copies of tirzepatide ended after the March 5, 2025 court decision. State-licensed pharmacies and physicians can no longer compound tirzepatide products that are essentially a copy of FDA-approved Zepbound or Mounjaro.
• 503B outsourcing facilities: Enforcement discretion ended on March 19, 2025.

After those dates, the enforcement discretion that specifically applied to tirzepatide ended. Licensed compounders shifted to producing personalized or combination formulations under the standard 503A and 503B rules that apply to all custom-prepared medications.¹

What Remains Available

Licensed 503A and 503B compounding pharmacies continue to produce personalized tirzepatide formulations, tirzepatide combined with vitamin B12, B6, glycine, niacinamide, or similar additions, under the patient-specific, prescription-based compounding framework that has always applied to custom preparations. These are not copies of FDA-approved Zepbound or Mounjaro; they're a distinct category with its own regulatory pathway.

Here's what to know about compounded tirzepatide in 2026:

1. Pricing and access are the main draw. Licensed compounders advertise personalized tirzepatide formulations at monthly prices ranging from roughly $150 to $600, plus typical membership or consultation fees of $40 to $100 at many telehealth platforms.⁹ For patients without insurance coverage who find LillyDirect out of reach, compounded options remain the most affordable path. Several larger telehealth providers, including Ro, have pivoted to selling brand-name Zepbound vials under Eli Lilly's capped self-pay program, while smaller independent compounders continue to focus on personalized formulations.⁸
2. Insurance and manufacturer savings cards don't apply. Compounded tirzepatide is self-pay.
3. Regulatory category differs from brand-name. Compounded medications are prepared by licensed 503A or 503B pharmacies under prescription, which is a different pathway than mass-produced, FDA-reviewed drugs like Zepbound or Mounjaro. Quality depends on the compounding pharmacy's state licensing and, where applicable, 503B registration. A good provider will share their pharmacy's licensing information and the specific formulation details on request.

Does insurance cover tirzepatide?

For most patients, whether insurance covers tirzepatide matters more than any other variable. A covered plan can drop the monthly cost from $1,086 to $25, a 43-fold difference. An excluded plan leaves the patient paying the full retail price.

Commercial insurance coverage falls into three patterns:

Scenario 1: Covered on Formulary

The plan's preferred drug list includes tirzepatide, usually on a mid-tier or specialty-tier level. Copays typically run $25 to $200 per month depending on tier. Prior authorization is common, especially for Zepbound, and typically requires documentation of BMI ≥30 (or ≥27 with a weight-related comorbidity), documentation of previous weight-loss attempts, and sometimes enrollment in a supporting lifestyle program.

Scenario 2: Covered After Prior Authorization

The plan will cover tirzepatide once clinical criteria are documented and approved. The paperwork burden falls on the prescriber's office, with the patient's cooperation on records and documentation. Approval rates vary by payer, but for patients who clearly meet BMI and comorbidity criteria, approvals are common. Mounjaro prior authorizations for documented Type 2 diabetes are straightforward; Zepbound authorizations for obesity have historically been more variable.

Scenario 3: Excluded

Some commercial plans, particularly smaller employer self-funded plans, explicitly exclude weight-loss medications. For these patients, the savings card's larger non-covered discount or LillyDirect is the fallback.

Does Medicare, Medicaid, or an HSA cover tirzepatide?

Medicare

Medicare Part D does not cover any prescription drug used primarily for weight loss. This is a statutory exclusion written into the Medicare Modernization Act of 2003. Zepbound is therefore not covered for its obesity indication on any Medicare plan. Mounjaro may be covered for Type 2 diabetes, subject to formulary placement and prior authorization on a specific Part D plan. The Centers for Medicare & Medicaid Services' Plan Finder is the authoritative place to check coverage for a specific plan and drug combination.

Bills to extend Medicare coverage to anti-obesity medications have been introduced in multiple Congressional sessions without passage. A 2026 Medicare Advantage plan that covers Zepbound for obesity is almost certainly applying a supplemental benefit that is not guaranteed to continue in subsequent plan years.

Medicaid

Medicaid coverage varies by state. Most state Medicaid programs cover Mounjaro for Type 2 diabetes with prior authorization requirements. Zepbound coverage for obesity is less consistent, a growing number of states cover it, often with BMI thresholds and documented comorbidities, while others continue to exclude weight-loss drugs entirely. State formulary decisions change annually during legislative and budget cycles, so current-year coverage is worth confirming with the state Medicaid program directly.

Veterans Affairs

The VA covers tirzepatide for enrolled veterans who meet specific clinical criteria. Copays depend on the veteran's priority group and service connection. The VA formulary and clinical eligibility criteria for GLP-1s have expanded over 2024–2026.

HSA and FSA Dollars

Both Health Savings Accounts and Flexible Spending Accounts can be used to pay for tirzepatide when prescribed. This effectively discounts the out-of-pocket cost by your marginal tax rate, for a patient in a 24% federal bracket paying $299/month to LillyDirect, HSA dollars turn that into approximately $227 after-tax equivalent. For patients without insurance coverage, HSA/FSA is one of the most overlooked cost levers.

What extra costs come with tirzepatide beyond the prescription?

Monthly drug cost is the headline figure, but it's not the whole picture. Budgeting for tirzepatide realistically means accounting for four additional line items that most cost-comparison articles skip.

Injection Supplies

Brand-name autoinjector pens include the injection device. LillyDirect vials require separately packaged syringes (Eli Lilly ships these with vial orders) and alcohol prep pads that patients typically buy at a pharmacy, roughly $5 to $15 per month out of pocket. Sharps disposal containers add another $10 to $20 every few months depending on state regulations.

Required Lab Work

Most prescribers require baseline and follow-up labs: A1C, fasting glucose, lipid panel, liver enzymes, and sometimes kidney function markers. For insured patients these are usually covered, though deductible-phase costs vary. For cash-pay patients, a baseline lab panel runs approximately $100 to $300 at direct-to-consumer labs, and periodic follow-ups add a similar amount one to two times per year.

Clinician Visits and Telehealth Consultations

Ongoing prescriptions require periodic clinician follow-ups, typically quarterly. For patients using compounded-tirzepatide telehealth platforms, these are usually bundled into the monthly cost. For patients using their primary care clinician, visit costs depend on insurance copays or cash-pay fees ($100 to $250 per visit for cash pay).

Time Cost of Insurance Appeals

Prior authorization and insurance appeals consume patient time. For a plan that denies an initial Zepbound claim, the appeal process typically involves the prescriber's office submitting clinical documentation, the plan requesting additional records, and sometimes a second denial leading to formal appeal. The time cost, measured in phone calls, records requests, and follow-up, is real, even when the prescriber's office handles most of it.

For a cash-pay patient on LillyDirect's 2.5 mg dose, the true total monthly cost is closer to $320 to $340 once supplies and amortized lab costs are included, rather than the $299 sticker price.

What is the cheapest way to get tirzepatide in 2026?

The cheapest legitimate tirzepatide cost for you depends on three questions:

1. Do you have commercial insurance? If yes, apply for the manufacturer savings card and ask your prescriber to submit a prior authorization. Covered patients pay $25 per month plus applicable deductibles.
2. If not covered by insurance, are you comfortable with vial injections? If yes, LillyDirect's Self Pay Journey Program at $299 to $449 per month is the cheapest FDA-approved path. If vials are a dealbreaker, the savings card's non-covered discount still beats retail.
3. Are you open to compounded tirzepatide? Licensed 503A and 503B compounding pharmacies produce personalized tirzepatide formulations at monthly prices that often undercut LillyDirect. Ask your provider which pharmacy dispenses your prescription and what the formulation contains, standard questions a reputable compounder is ready to answer. For a provider-by-provider breakdown, see our compounded-tirzepatide provider reviews (coming soon).

For patients who reach the maintenance dose, total annual cost varies enormously:

• Insurance + savings card (any dose): ~$300 per year
• LillyDirect Self Pay Journey Program, 15 mg: ~$5,388 per year
• Retail pharmacy list price, 15 mg: ~$13,000 per year
• Compounded personalized formulation (mid-range pricing per secondary trackers): ~$3,000 to $6,000 per year⁹

Frequently Asked Questions

How much does tirzepatide cost per month in 2026?

Brand-name tirzepatide lists at roughly $1,080 to $1,086 per 28-day supply. Through LillyDirect, Zepbound single-dose vials start at $299 per month for the 2.5 mg dose. With commercial insurance and a manufacturer savings card, eligible patients can pay as little as $25 per fill. Compounded alternatives vary by provider and dose.

Is compounded tirzepatide still legal?

After the FDA declared the tirzepatide shortage resolved in December 2024 and a federal court denied a preliminary injunction on March 5, 2025, the enforcement-discretion window closed. State-licensed (503A) pharmacies could no longer compound copies of tirzepatide, and outsourcing facilities (503B) lost their window on March 19, 2025. Providers still offering personalized or combination formulations do so under a narrower regulatory pathway.

Does insurance cover tirzepatide for weight loss?

Commercial coverage is uneven. Employers increasingly cover Zepbound for clinically eligible patients, typically with prior authorization and BMI documentation. Medicare Part D does not cover any prescription used primarily for weight loss. Mounjaro for Type 2 diabetes is more widely covered than Zepbound for obesity across most plan types.

What is the cheapest way to get tirzepatide legally?

For commercially insured patients whose plan covers the drug, the manufacturer savings card brings the price to around $25 per month. For cash-pay patients, Zepbound single-dose vials through LillyDirect at $299 to $699 per month are the cheapest path to FDA-approved tirzepatide. Compounded alternatives can undercut this but come with different regulatory and safety considerations.

Is there a generic version of tirzepatide?

No. Tirzepatide is under patent protection held by Eli Lilly, with patent expiry not expected until the early 2030s. Compounded tirzepatide is not a generic. It is produced under a separate regulatory pathway governing compounded preparations, not FDA-approved abbreviated new drug applications.

What is the LillyDirect Self Pay Journey Program?

The Zepbound Self Pay Journey Program offers reduced monthly pricing on higher-dose single-dose vials for cash-pay patients who maintain consistent refills. Patients who refill within 45 days of the prior delivery qualify for $449 per month on the 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses, compared to the regular $499 to $699 range for those same doses outside the program.

The Bottom Line

Tirzepatide cost in 2026 is no longer a single number. The spread between the cheapest and most expensive legitimate monthly path is roughly 50-to-1, and the answer for any given patient depends on whether their insurance covers the drug, whether they're comfortable with vial injections, and whether the post-March 2025 compounded market fits their situation. For insured patients the order is clear: apply the savings card, take the $25 monthly price. For cash-pay patients the answer is LillyDirect at $299 to $449 per month through the Self Pay Journey Program. Compounded alternatives exist but have narrowed, and the regulatory category matters.

Before committing to any path, confirm current pricing directly with the provider, verify insurance coverage with your plan's member services line, and have a clear conversation with your prescriber about whether tirzepatide, at your specific cost, is the right choice versus alternatives like semaglutide or intensive lifestyle intervention. For a head-to-head molecule comparison, see our semaglutide vs. tirzepatide guide.